Pharmaceutical industry – Page 32
-
-
BusinessStandard antibody will bolster biopharma
New NIST reference material will help validate and compare analytical techniques
-
BusinessAmgen and Advaxis partner on immuno-oncology
Deal covers rights to system for building cancer therapies specific to a patient’s own tumours
-
BusinessJob cuts at Takeda, Boehringer and Arena
Hundreds of positions eliminated as companies re-evaluate R&D
-
BusinessCelgene and Jounce team up against cancer
Firms promise next-generation immuno-oncology as existing drugs rack up successes
-
BusinessJuno CAR-T trial suspended after patient deaths
Immunotherapy study restarted with amended pre-treatment protocol
-
OpinionTime for better incentives to keep drug costs low
Getting outraged at drug price hikes is all very well, but we need more constructive options
-
BusinessAll part of the service
Simon Hirst, founder of contract research organisation Sygnature, is the 2016 Chemistry World entrepreneur of the year
-
BusinessUnpicking doctor payments
Accepting even small meals from drug industry reps appears to influence doctors’ prescription rates
-
BusinessAstraZeneca licenses skin drugs to Leo
Offloading psoriasis and dermatitis antibodies continues AZ’s plan to refocus on fewer therapy areas
-
BusinessNovartis partners with Xencor for cancer antibodies
Deal deepens Novartis’s focus on immuno-oncology
-
BusinessLies and deception see Astellas UK suspended by trade body
Company promoted drugs inappropriately and misled regulators in the resulting investigation
-
BusinessSanofi and Boehringer agree €11bn asset swap
Deal swaps Sanofi’s animal health arm for Boehringer’s consumer healthcare business as both firms aim to boost scale
-
BusinessHarvard settles with ex-student over drug royalties
Student claimed university forced him to accept unfair cut in patent deal
-
Business
Teva sells off products in preparation for Allergan merger
Generics deals with Impax, Dr Reddy’s and Sagent aimed at satisfying competition authorities
-
BusinessUS biotech director accused of insider trading
Biostatistics chief at Akebia charged with securities fraud
-
BusinessJudge voids Merck & Co’s $200m patent claim
‘Serious misconduct’ kills case over Gilead’s hepatitis C drugs
-
BusinessAdventures of an accidental entrepreneur
India needs to break out of its colonial mindset and tap into its innovative potential, says Biocon chief Kiran Mazumdar-Shaw
-
Business
Merck & Co to buy Afferent for neurology drugs
Deal worth up to $1.25bn includes drug candidate for chronic coughs
-
ResearchConnections in flow
MIT’s Klavs Jensen tells us how his research ranges in size from a chip, to a fridge to a shipping container